Achieve Life Sciences reported a net loss of $74.8 million for the second quarter of 2026, a result heavily impacted by a $48.7 million non-cash warrant liability charge. The company significantly strengthened its balance sheet, ending the quarter with $187.3 million in cash and equivalents to fund the transition of manufacturing to the United States and the planned commercialization of cytisinicline.
Key Highlights
- Management plans to resubmit the New Drug Application (NDA) for cytisinicline in the fourth quarter of 2026, following the successful manufacturing transition to Adare Pharma Solutions to resolve previous FDA observations.
- The company secured a private placement of up to $354 million, with $180 million received upfront and an additional $174 million tied to milestone-based warrants exercisable around FDA approval.
- FDA feedback in the Complete Response Letter was limited to manufacturing and labeling, specifically identifying no deficiencies related to the clinical efficacy or safety of the lead candidate.